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BioenergeticsBackground: Complex I (CI) deﬁciency is the most frequent cause of OXPHOS disorders. Recent studies have
shown increases in reactive oxygen species (ROS) production and mitochondrial network disturbances in
patients' ﬁbroblasts harbouring mutations in CI subunits. Objectives: The present work evaluates the impact
of mutations in the NDUFA1 and NDUFV1 genes of CI on mitochondrial bioenergetics and dynamics, in
ﬁbroblasts from patients suffering isolated CI deﬁciency. Results: Decreased oxygen consumption rate and
slow growth rate were found in patients with severe CI deﬁciency. Mitochondrial diameter was slightly
increased in patients' cells cultured in galactose or treated with 2′-deoxyglucose without evidence of
mitochondrial fragmentation. Expression levels of the main proteins involved in mitochondrial dynamics,
OPA1, MFN2, and DRP1, were slightly augmented in all patients' cells lines. The study of mitochondrial
dynamics showed delayed recovery of the mitochondrial network after treatment with the uncoupler
carbonyl cyanide m-chlorophenyl hydrazone (cccp) in patients with severe CI deﬁciency. Intracellular ROS
levels were not increased neither in glucose nor galactose medium in patients' ﬁbroblasts. Conclusion: Our
main ﬁnding was that severe CI deﬁciency in patients harbouring mutations in the NDUFA1 and NDUFV1
genes is linked to a delayed mitochondrial network recovery after cccp treatment. However, the CI deﬁciency
is neither associated with massive mitochondrial fragmentation nor with increased ROS levels. The different
genetic backgrounds of patients with OXPHOS disorders would explain, at least partially, differences in the
pathophysiological manifestations of CI deﬁciency.tal Universitario 12 de Octubre.
90 8001; fax:+34 91 390 8544.
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Complex I (CI), the largest component of the respiratory chain, is
the ﬁrst entry point of electrons into the oxidative phosphorylation
(OXPHOS) system, and catalyzes the transfer of two electrons from
NADH to ubiquinone. One of the 14 CI catalytic subunits is the
NDUFV1 protein, which is encoded by the NDUFV1 gene. This protein
contains the NADH-binding site and the primary electron acceptor
FMN [1]. CI also includes at least 31 accessory proteins of yet poorly
understood functions, one of which is an integral membrane protein
known as MWFE or NDUFA1, encoded by the X-linked gene NDUFA1
[2]. The NDUFA1 protein is essential for CI function in mammalian
mitochondria as it plays a role in CI stability, synthesis of the catalytic
mitochondrial-encoded ND subunits and in their incorporation intothe complex [3–5]. It has been hypothesized that phosphorylation
could be implicated in the regulation of the complex activity [6,7],
NDUFA1 phosphorylation at serine 55 being one of the phosphory-
lation sites that could affect CI function [8].
Dysfunction of the respiratory chain is the most frequent inborn
error of metabolism [9]. CI deﬁciency is responsible for 40% of the
OXPHOS disorders [10]. Mutations in several subunits and CI assembly
factors have been associated with CI deﬁciencies [for a review see
1,11,12]. Recent studies revealed increases in reactive oxygen species
(ROS) production [13–15] andmitochondrial network disturbances in
patients' ﬁbroblasts harbouring mutations in CI subunits [16–19].
In ﬁbroblasts and other cells, mitochondria form a reticulum
where they experience continuous cycles of fusion and ﬁssion during
proliferation [20] mediated by speciﬁc proteins, such as mitofusins 1
and 2 (MFN1, MFN2), OPA1 and dynamin related protein 1 (DRP1)
[21]. Some ﬁbroblast lines derived from OXPHOS-deﬁcient patients
display a decrease in the branching and length of mitochondrial
tubules that could reﬂect compromised mitochondrial homeostasis;
other cells show an outgrow of the overall mitochondrial network
that may indicate a compensative phenomenon [22]. Although a
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OXPHOS disorders has been reported, the possible alterations and
role of ﬁssion and fusion proteins in these diseases has been scarcely
studied [23,24].
The aim of the present study was to evaluate the impact of
mutations in NDUFV1, and NDUFA1 genes on mitochondrial bioener-
getics and dynamics by using patients' ﬁbroblasts.
2. Material and methods
2.1. Subjects
Patient 1 (P1) is a boy suffering acidosis, leukoencephalopathy and
epilepsy, and harbouring W51X and T423Mmutations in the NDUFV1
gene who reached 14 months of age. Patient 2 (P2) and patient 3 (P3)
were two unrelated male patients presenting R37S and G8R
hemizygous mutations in the NDUFA1 gene, respectively [25]. These
mutations were associated with developmental delay and myoclonic
epilepsy (P2) and Leigh syndrome (P3). P2 has already reached
10 years of age, while P3 died at 14 months of age of cardiorespiratory
arrest during a respiratory infection.
2.2. Cell culture and treatments
Fibroblasts were obtained from skin biopsies and cultured in
DMEM (i) with high glucose (4.5 g/L) (DMEM-Glu), or (ii) with no
glucose but containing galactose (4.5 g/L) supplemented with 10%
fetal calf serum, penicillin 50 IU/mL and streptomycin 50 IU/mL
(DMEM-Gal); for glycolysis inhibition, cells were maintained in (iii)
DMEM-Gal with 40 mM deoxyglucose for 8 h. The three media
employed also contained 2 mM glutamine and 100 mM pyruvate.
Mitochondrial dynamics was studied by inducing mitochondrial
network fragmentation after treatment with the uncoupler carbonyl
cyanide m-chlorophenyl hydrazone (cccp) 10 µM, for 4 h, and a
subsequent recovery period of 4 h as described by Guillery et al. [19].
2.3. Enzyme activities of mitochondrial respiratory chain complexes
Mitochondrial respiratory chain complexes were assayed in
sonicated suspensions of cultured skin ﬁbroblast according to
established methods [26]. The enzyme activities were corrected by
citrate synthase activity, a classical marker of cellular mitochondrial
content.
2.4. ATP content measurements
Cellular ATP was extracted from cells grown in DMEM-Glu,
DMEM-Gal and DMEM-Gal-grown cells incubated with 40 mM 2′-
deoxyglucose for 4 h, in boiling 100 mMTris, 4 mM EDTA pH 7.75, and
assayed by bioluminescence using a luciferin–luciferase system
(Roche) according to manufacturer's instructions. ATP concentration
was corrected per mg of protein.
2.5. RT-PCR
Relative quantiﬁcation of mtDNA versus nuclear DNA was
performed by real-time PCR in a HT Real Time PCR System (Applied
Biosystems, Foster City, CA, USA), using isolated DNA from control and
patient's ﬁbroblasts as described elsewhere [27].
2.6. Determination of aerobic glycolysis
For the determination of aerobic glycolysis cells were cultured in
glucose; at the beginning of the experiment the culture media was
replaced by fresh DMEM-Glu with or without 6 µM oligomycin; 2 hlater, 0.1 mL aliquots of culture media were collected for the
enzymatic determination of lactate [28].2.7. Oxygen consumption
Oxygen consumption rate (OCR) in adherent ﬁbroblasts was
measured with a XF24 Extracellular Flux Analyzer (Seahorse
Bioscience, Billerica, MA, USA). Control and patients' ﬁbroblasts
were seeded in XF 24-well cell culture microplates (Seahorse
Bioscience) at 12.5×103 cells/well in 250 µL of DMEM-Glu or
DMEM-Gal, and incubated at 37 °C/5% CO2 for 24 h. Assays were
initiated by replacing the growth medium from each well with
700 µL of unbuffered DMEM-Glu or DMEM-Gal prewarmed at 37 °C.
The cells were incubated at 37 °C for 60 min to allow media
temperature and pH to reach equilibrium before the ﬁrst rate
measurement. After an OCR baseline measurement, 50 µL of
oligomycin (OL), carbonyl cyanide 4-(triﬂuoromethoxy)phenylhy-
drazone (FCCP), rotenone (RO) and nitropropionic acid (NPA)
solutions were sequentially added to each well to reach working
concentrations of 6 µM, 50 µM, 1 µM and 10 µM respectively, and
changes in the OCR were analyzed.
Data were expressed as pmol of O2 per minute per 106 cells and
normalized by mitochondrial mass determined by ﬂow cytometry
(nonyl acridine orange, NAO, ﬂuorescence arbitrary units). Maximal
respiratory rate was calculated as the difference between the OCR
after FCCP injection and the lowest OCR reached after rotenone
addition. Oligomycin sensitive respiration rate (OSR) was calculated
as the difference between the basal OCR and the OCR after oligomycin
injection. OSR expressed as the percentage of the maximal respiratory
rate in each cell line represents mitochondrial coupling.2.8. Immunoﬂuorescence microscopy
Immunoﬂuorescence was performed on sub-conﬂuent parafor-
maldehyde-ﬁxed cells. Antigen retrieval, when needed, was per-
formed by submerging the coverslips in 100 mM Tris pH 9.5, 5% urea
for 10 min at 95 °C. Coverslips were PBS washed, and permeabilized
for 15 min with 0.1% Triton X-100. Cells were incubated in blocking
buffer containing 10% goat serum for 1 h at room temperature. The
mouse monoclonal anti-complex V α subunit (MitoSciences), or anti-
Porin (MitoSciences) were used as primary antibodies. Texas Red-
conjugated anti-mouse (MitoSciences) was used as secondary
antibody. After appropriate rinsing, coverslips were mounted in
ProLong Gold antifade reagent (Molecular Probes) on glass slides and
cells were viewed with a Zeiss LSM 510 Meta confocal microscope
with a 63× planapochromat objective.2.9. Analysis of intracellular ROS in live cells by confocal microscopy
Cells grown on coverslips were loaded with 5 μM 2′,7′-dichloro-
ﬂuorescin diacetate (DCF-DA, Sigma) for 20 min in the dark in a CO2
incubator. DCF-DA is a nonpolar and nonﬂuorescent compound,
which diffuses into the cells and is hydrolyzed to polar 2′,7′-
dichloroﬂuorescin, thereby trapped within the cells. Subsequently
intracellular 2′,7′-dichloroﬂuorescin is rapidly oxidized to highly
ﬂuorescent 2′,7′-dichloroﬂuorescein in the presence of ROS or
hydrogen peroxide in the cells [29]. After loading, the dye was
removed and cells washed twice with PBS before image collection
with a Zeiss LSM 510 Meta confocal microscope. The image collection
was carried out with a 20× lens using the 488 nm excitation laser line.
As positive control, human ﬁbroblasts from patients suffering
mitochondrial respiratory chain complex III deﬁciency producing
signiﬁcant amounts of ROS were analyzed in parallel.
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The ﬂuorescent probes NAO (Molecular Probes) and 2′,7′-
dichloroﬂuorescin diacetate (DCF-DA, Sigma) were used to analyze
cardiolipin, as a marker of cellular mitochondrial content, and ROS
production respectively, using ﬂow cytometry. The cellular ﬂuores-
cence intensity was measured using a FACScan ﬂow cytometer
(Beckton-Dickinson). For each analysis 10,000 events were recorded.
2.11. Western blot analysis in cell lysates
Fibroblasts grown either in DMEM-Glu or DMEM-Gal were lysated
in 5 mM Tris pH 8.0, 20 mM EDTA, 0.5% Triton X-100 and 100 µg/mL
of protease inhibitors, centrifuged at 11,000×g, and supernatant was
collected. Protein content of the supernatants (cell lysates) was
determined [30]. Samples of cell lysates (10 µg) were used to perform
semiquantitative analysis of DRP1, MFN2 and OPA1 protein levels by
immunoblotting (Western Blot). SDS-PAGE was performed on a 7.5%
separation gel for proteins involved in fusion and ﬁssion, whereas 15%
and 12% separating gels were used for western blot analysis of GAPDH
and antioxidant enzymes, respectively. Resolved proteins were
transferred to a PVDF membrane. Blots were blocked and incubated
with the following primary antibodies: mouse anti-DLP1 (BD
Transduction Laboratories™), mouse anti-OPA1 (BD Transduction
Laboratories™), mouse anti-MFN2 (Abnova), anti-GAPDH (Abcam),
rabbit anti-mtSOD (mitochondrial superoxide dismutase, Sigma),
mouse anti-CAT (catalase, Sigma) and rabbit anti-GR (gluthathione
reductase, Abcam). Immunodetection of primary antibodies was
carried out with peroxidase-conjugated goat anti-mouse antibody
(Molecular Probes). The signal was detected with Enzyme Chemilu-
minescence (Amersham Biosciences). Band densities were evaluated
by densitometric scanning (Image J software). To verify that the total
protein amount loaded in each lane was the same, β actin orα tubulin
were immunodetected with mouse anti-β actin or anti-α tubulin
(Sigma) coupled to peroxidase-conjugated goat anti-mouse antibody
(Molecular Probes).
2.12. Data analysis
All determinations were performed at least in duplicate. Data are
presented as mean±standard deviation (SD). Statistical analysis was
performed with the SPSS software (SPSS, Chicago, IL). Mean NAO
ﬂuorescence andmtDNA content of n=3–8 samples are presented; to
analyze the group effect on these parameters a Kruskal–Wallis test
was performed, with statistical signiﬁcance set at P≤0.05. Immuno-
ﬂuorescence photographs were analyzed with Image J software
(http://rsbweb.nih.gov/ij/). Mitochondrial diameter was determinedTable 1
Activities of the mitocondrial respiratory chain enzymes in ﬁbroblasts derived from the
patients.
CS CI CII CIII CIV
Glucose
Control
(n=5)
66–94 21.6–34.7 12.8–27.4 31.1–50.9 89–120
P1 77 7.7 23.6 48.7 86
P2 87 19.0 25.3 39.7 123
P3 106 8.8 16.4 32.6 91.4
Galactose
Control
(n=5)
72–84 21.0–28.4 19.0–29.4 20.8–45.2 104–123
P1 63 9.6 27.3 54.0 149
P2 81 18.8 27.3 42.4 141
P3 109 9.54 14.8 30.4 107
Abnormal values are indicated in boldface.
Enzyme activities are expressed in cU/U CS.
Citrate synthase (CS) activity is expressed as nmol min−1 mg−1.as follows: after calibrating the images according to the objective
employed to obtain the photographs, the mitochondrial width was
measured with Image J software; results were presented as mean
(±SD) values of 200 determinations. In the present work 4 control
cell lines were analyzed. For every condition tested, the width of 200
mitochondria in 10 cells representative of the mitochondrial
morphology was determined. To analyze ATP concentration, extra-
celullar lactate levels andmitochondrial diameter in ﬁbroblasts grown
in different culture media, we performed a two-way ANOVA that
allowed us to assess the two main effects, i.e. group (control or
patient) and treatment (−OL/+OL) or growth medium (DMEM-Glu,
DMEM-Gal or Gal+Deoxyglucose), as well as the interactionFig. 1. Mitochondrial mass and growth rate in galactose. A) Flow cytometry
determination of mitochondrial mass in control (C) and patients' skin ﬁbroblasts (P1,
P2, P3) stained with NAO probe. *Pb0.05 for P3 vs rest of cells lines. B) Relative
quantiﬁcation of mtDNA vs nuclear DNA by real-time PCR, data are presented as
percentage of controls. *Pb0.05, for P3 vs the rest of the cell lines. C) Mean growth rates
in DMEM-Gal. Data are presented as mean value±SD (n=3).
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treatment on mitochondrial diameter we used a two-way ANOVA
with repeated measures that allowed us to test the two main effects
(group and treatment) and the group⁎ treatment interaction effect.
The Scheffé test was employed post hoc to determine the differences
between groups. A level of P≤0.05 was selected to indicate statistical
signiﬁcance.3. Results
As expected, all the ﬁbroblast lines derived from the patients
showed decreased CI activity in both DMEM-Glu and DMEM-Gal
media (Table 1). In DMEM-Gal medium the range of CII and CIV
activities shifted toward higher values in the control ﬁbroblasts. In the
patients' cells grown in DMEM-Gal a slight increase in CI activity was
detected in P1 and P3 cells in comparison with glucose-grown cells.
Also, in DMEM-Gal the activities of CII and CIII were augmented in P1
and P2, and CIV activity was increased in the three patients. These
results, that reﬂect an adaptation to this metabolic environment,
correlate with previous data showing augmented expression levels of
some respiratory chain subunits in galactose-grown ﬁbroblasts [31].
The CS activity, an indicator of cellular mitochondrial content, was
slightly increased in P3 in both culture media (Table 1). Flow
cytometry analysis showed a marked increase in cardiolipin in P3
(Pb0.05) (Fig. 1A); mtDNA content determination by real-time PCRFig. 2. Oxygen consumption. Real-time analysis of oxygen consumption rate (OCR) in contro
cells respiring in DMEM-Glu (A) and DMEM-Gal (B). Oligomycin (OL), FCCP, rotenone (RO) a
arrows into each well containing 12,500 cells after baseline measurements. Data are expres
mass as assessed by NAO ﬂuorescence. Basal OCR in controls respiring in DMEM-Glu was 96
represents oxidative phosphorylation rate, was calculated as percentage of maximal respiraalso indicated a signiﬁcant increase inmtDNA in P3 (Pb0.05) (Fig. 1B).
The results obtained by these three approaches support the presence
of an increased mitochondrial content in P3.
When cells are grown in DMEM-Gal, galactose enters slowly the
glycolysis [32], and in such condition, patients' ﬁbroblasts showed a
strong reduction in growth rate compared with control cells, with the
mildest decrease being observed in P2 (Fig. 1C). A milder decrease in
growth rate was also detected in the patient's ﬁbroblasts cultured in
DMEM-Glu (data not shown).3.1. Mutations in CI alter mitochondrial bioenergetics
The XF24 Extracellular Flux Analyzer allows determination of OCR
in adherent cells [33]. In order to determine oligomycin sensitive
respiration, maximal respiration, and oxygen consumption due to CI
and complex II activity, OL, FCCP, RO and NPAwere sequentially added
to the attached cells (Fig. 2). The qualitative analysis of the results
obtained showed that all cell lines displayed similar bioenergetic
proﬁles in DMEM-Glu (Fig. 2A) and DMEM-Gal (Fig. 2B). After OL
injection OCR was decreased, and maximal respiratory rate was
achieved after FCCP addition. The basal respiratory rates observed in
the present work are half of the maximal ones, according to previous
data obtained in human ﬁbroblasts by Gnaiger et al. [34]. Rotenone
treatment induced a strong decrease in OCR, setting the respiration
near zero values, and therefore, NPA addition was unable to induce al (C) and patients' cells (P1, P2, P3) determined with XF24 Extracellular Flux Analyzer in
nd nitropropionic acid (NPA) were injected sequentially at the time points indicated by
sed as pmol of O2 per minute per 106 cells, and normalized per units of mitochondrial
.7±19 (pmol O2/min/12,500 cells), n=8. Oligomycin sensitive respiration rate, which
tory rate.
Fig. 3. ATP levels and Glycolytic ﬂux. A) Cellular ATP content in control (C) and patient's
cell grown in DMEM-Glu, DMEM-Gal and cells after 4 h incubation with galactose
medium with deoxyglucose (Gal+Deoxyglucose). Two-way ANOVA analysis: signif-
icant main effect for group (Pb0.001), treatment (Pb0.001) and interaction between
them (Pb0.001). Glycolytic ﬂux estimated by lactate release to the extracellular
medium. B) Lactate levels in DMEM-Glu culture medium of ﬁbroblasts nontreated
(−OL) and treated with oligomycin (+OL). Two-way ANOVA analysis: signiﬁcant main
effect for group effect *(Pb0.05). C) Expression levels of the key glycolytic enzyme,
GAPDH, and loading control with α-tubulin, in control (C), and patients' cells (P1, P2,
P3) cultured in high glucose medium.
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inhibition of CI by rotenone may increase the cellular NADH/NAD+
ratio, leading to inhibition of α-ketoglutarate dehydrogenase activity
and, subsequently succinate production. This phenomenon would
stall CII activity, and thus might explain the strong inhibition of
respiration in adherent cells treated with rotenone that we observed
in the present study.
In DMEM-Glu, P1 and P3 showed decreased basal and maximal OCR,
whereas P2 presented normal values in comparison with control cells
(Fig. 2A).Whencellswere respiring inDMEM-Gal, basal andmaximalOCR
did not change in control ﬁbroblasts in comparison with DMEM-Glu
conditions (Fig. 2B). In P1, the basal and maximal OCR increased with
DMEM-Gal, but still remained below control values. A slight increase in
basal OCR was shown in P2, although maximal OCR did not change.
Finally, P3 ﬁbroblasts were unable to increase their basal and maximal
OCR in DMEM-Gal, and remained signiﬁcantly below control values.
Oligomycin sensitive respiration rate (OSR) represents the activity
of oxidative phosphorylation (Fig. 2), that is, the synthesis of ATP by
complex V coupled to the activity of the respiratory chain. When
expressed as percentage of maximal respiratory rate, OSR represents
the degree of mitochondrial coupling. Control and patients' cells
showed a similar degree of mitochondrial coupling, which indicates
that patients' ﬁbroblasts did not suffer any alteration in oxidative
phosphorylation. Nevertheless, the diminished basal OCR shown in P1
and P3 (37% and 58% of the control value respectively) may have
induced a reduction in ATP synthesis by OXPHOS system in these cells
lines. When cultured in DMEM-Gal, all the cell lines experienced an
increase in OSR (mean OSR in glucose 31.5±4 vs 43.6±4 in
galactose), reﬂecting increased mitochondrial coupling and, as
expected, increased ATP synthesis through the OXPHOS system.
ATP content was signiﬁcantly decreased in all patients' cells grown
in glucose, in comparison with control ﬁbroblasts, a further decrease
in this parameter was detected in galactose-grown P1 and P3 cells
(Pb0.001) (Fig. 3A). Treatment with 2′-deoxyglucose induced a
marked decrease in ATP content in all cell lines, including ﬁbroblasts;
this result suggests that, even in DMEM-Gal, glycolysis is contributing
to ATP production in all cell lines.
To assess the contribution of glycolysis to the ATP production in
DMEM-Glu, glycolyticﬂuxwas estimated by lactate release (Fig. 3B). Only
P3 showed an increased basal lactate production rate in DMEM-Glu
(Pb0.001) (Fig. 3A)when compared to control or other patients, strongly
suggesting the pathogenicity of the NDUFA1 mutation in cellular
bioenergetics [35,36]. The rates of glycolytic ﬂux after OL treatment
were marginally affected in the different cell lines (PN0.05 for OL
treatment) (Fig. 3B), indicating that glycolysis was running at maximal
capacity in all cell lines. In agreement with this ﬁnding, the expression
levels of GAPDH, a key enzymeof the glycolytic pathway,were not altered
in patients' cells in comparison with control ﬁbroblasts (Fig. 3C).
3.2. CI deﬁciency promotes a delay in mitochondrial network recovery
The transversal section (width) of a mitochondrion is the most
stable dimension of this organelle and variations in this variable
reﬂect an alteration of themitochondrial morphology [37].When cells
are grown in DMEM-Glu, mitochondrial network in control ﬁbroblasts
is composed of long branched mitochondrial ﬁlaments (Fig. 4A) and
overall mitochondrial morphology in nonsynchronized cultures is
similar to that observed in G0-arrested cells (data not shown). Under
this condition, patients' cells showed essentially a normal mitochon-
drial architecture and mitochondrial width; yet in P3 an increased
mitochondrial content was observed, which is consistent with the
increasedmitochondrial mass shown by ﬂow cytometry and real-time
PCR (Fig. 1). When glucose was substituted by galactose, both control
and OXPHOS defective ﬁbroblasts were able to maintain normal
mitochondrial morphology (Fig. 4A) and only a slight increase in
mitochondrial diameter was found in all cell lines (Fig. 4B). In order toforce cells to rely only in respiratory chain to obtain energy, cells were
maintained in DMEM-Gal with 2′-deoxyglucose, a potent inhibitor of
glycolysis. Although some abnormal structures appeared in the
presence of deoxyglucose, most of the cells were able to maintain a
normal mitochondrial architecture (Fig. 4A) and the mitochondrial
diameter was slightly augmented as in DMEM-Gal (Fig. 4B).
A slight increase in the main proteins implicated in mitochondrial
fusion and ﬁssion, OPA1, and DRP1, was observed in the patients' cells
under glucose conditions (Fig. 5). When ﬁbroblasts were cultured in
DMEM-Gal, increases inOPA-1 andMFN2were found in both P2 and P3,
and DRP1 levels were increased in the three patients. In the two culture
conditions analyzed, DMEM-Glu and DMEM-Gal, the long isoforms of
OPA1 were predominant in both control and patient's cells.
Fig. 4. Mitochondrial network morphology. A) Typical mitochondrial network morphology in control (C), patient's skin ﬁbroblast (P1, P2, P3) grown in high glucose medium
(DMEM-Glu), galactose medium (DMEM-Gal) and after 8 h in galactose medium with deoxyglucose (Gal+Deoxyglucose). Cells were ﬁxed with paraformaldehyde and
immunoﬂuorescence against complex V alpha subunit was performed. B) Mitochondrial diameter in DMEM-Glu grown ﬁbroblasts (Glucose), DMEM-Gal grown ﬁbroblasts
(Galactose) and after 8 h in galactose with deoxyglucose medium (Galactose+D). The results shown are the means±SD of 200 determinations. Two-way ANOVA analysis:
signiﬁcant main effect for group (Pb0.001), treatment (Pb0.001) and interaction between them (Pb0.001). *(Pb0.001) signiﬁcantly different from DMEM-Glu diameter.
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cells treated with cccp as described by Guillery et al. [19] (Fig. 6A).
After 4 h of treatment with the protonophore, control and patients'
cells displayed amarkedmitochondrial fragmentation that resulted in
a signiﬁcant increase in mitochondrial diameter (Fig. 6B). This result
demonstrates efﬁcient mitochondrial ﬁssion in the three patients.
After a 4-hour recovery period in freshmedium devoid of cccp, control
and P2 cells almost recovered the previous mitochondrial tubular
network, but P1 and P3 showed signiﬁcantly increased mitochondrial
diameter that reﬂected a delay in the recovery of their initial
mitochondrial morphology (Pb0.001).3.3. ROS production
The ROS levels in living ﬁbroblasts were estimated as DCF-DA
ﬂuorescence using confocal microscopy (Fig. 7A). In control and
patients' cell lines ﬂuorescence levels in ﬂuorophore-loaded cells
cultured in both DMEM-Glu and DMEM-Gal were similar to those
detected in non-loaded ﬁbroblasts. This result demonstrates that
basal DCF-DA detectable ROS levels were below the detection limit in
both control and patients cells. Flow cytometry analysis of ROS
production in cells respiring in DMEM-Glu, conﬁrmed the results
obtained with confocal microscopy, as no differences between
Fig. 5. Expression levels of fusion and ﬁssion proteins. Expression levels of OPA-1, MFN2, DRP1 of ﬁbroblast grown in DMEM-Glu and DMEM-Gal determined byWestern blotting as
described in Materials and methods. β-actin was used as a loading control.
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the cellular antioxidant defences, we analyzed the expression levels of
some of the main antioxidant enzymes in glucose-grown cells
(Fig. 7D). The results obtained showed a signiﬁcant increase in
mtSOD levels only in P2, whereas, CAT and GR expression levels were
within the control range in all patients' cell lines.
4. Discussion
Our main ﬁnding was that severe CI deﬁciency in NDUFA1 and
NDUFV1mutant patients is linked to a delayedmitochondrial network
recovery after cccp treatment. However, the CI deﬁciency is neither
associated with massive mitochondrial fragmentation nor with
increased ROS levels. The different genetic backgrounds of patients
with OXPHOS disorders would partially explain the differences in the
pathophysiological manifestations of CI deﬁciency. There were several
novel aspects in our investigation. To date only three NDUFA1 human
mutants have been reported [25,38] and no functional study has been
performed in human cell lines derived from these patients. Potlury et
al. [38] recently analyzed the effects of the NDUFA1 mutations
reported here in a hamster cell line. On the other hand, only two
NDUFV1mutants have been studied with discrepancies in the ﬁndings
concerning mitochondrial morphology and ROS production [39].
The bioenergetic analysis with the XF24 Extracellular Flux
Analyzer demonstrated those patients with more severe CI deﬁciency
had decreased basal and maximal OCR, a ﬁnding that correlates well
with their worse clinical courses (P1 reached 14 months of age and P3
died at 14 months, whereas P2 reached 10 years of age) and growth
rate. The efﬁciency of oxidative phosphorylation was unaffected in the
patients, which is in accordance with previous research by Caissereau
et al. [40], reporting no alterations in OXPHOS coupling in CI-deﬁcient
ﬁbroblasts harbouring mutations in GDAP1.
Mitochondria are dynamic organelles undergoing continuous cycles
of fusion and ﬁssion especially visible during proliferation [20]. The
equilibrium between these two opposite processes deﬁnes the overall
architecture of themitochondrial network inhealthy cells. Alterations in
mitochondrial morphology have been recently linked to several
mitochondrial diseases, supporting the relationship between energyproduction and mitochondrial morphology [16–19]. It has been
proposed that CI deﬁciency and the degree ofmitochondrial complexity
(mitochondrial length and branching) could be mutually dependent
phenomena [10]. Large reductions in CI activity have been associated
with a decrease in mitochondrial mass and/or enhanced ﬁssion,
whereas moderate deﬁciencies have been linked with increased
mitochondrial mass [10,39]. In the present work, P1 and P3 showed a
severe and more pronounced decrease in CI activity than P2 (36% and
41% vs 88% of the lowest control value, respectively) but no evidence of
mitochondrial fragmentation. On the contrary, increasedmitochondrial
content composedby long tubularmitochondriawas shown inP3.Other
authors also described ﬁbroblasts from patients suffering severe CI
deﬁciency, yet exhibiting ﬁlamentous mitochondrial morphology
[19,41]. In addition, two patients harbouring the same mutations in
NDUFV1 and a similar degree of CI deﬁciency displayed opposite
mitochondrial morphologies [10,39]. These results suggest that low
residual CI activity is not always associated with a fragmented
mitochondrial network. The different genetic background in each CI-
deﬁcient patient, e.g. genes that mediate compensatory mechanisms or
genes encoding other OXPHOS subunits, could affect the pathophysi-
ological phenotype found in patients' cells. Such interactions could
partially explain discrepant observations of mitochondrial morphology
among studies or even between patients harbouring the same
mutations. In this regard, Potlury et al. [38] recently suggested that
synergistic interactions betweenmtDNAandnDNAencoded subunits of
the OXPHOS system, affect CI defects. This phenomenon could be of
great importance in NDUFA1mutants, as the NDUFA1 protein is known
to interact with severalmitochondrial-encoded ND subunits [4]. Finally,
different methodological approaches, i.e. culture media, could also
explain, partially discrepancies between studies.
It has been described that under basal culture conditions with high
glucose availability, ﬁbroblasts obtain most of the energy from
glycolysis [19,31]. Our data support this hypothesis because, in
DMEM-Glu, glycolysis is running at its maximal capacity. In the
patients' cells, where glycolysis was also working actively, the
decreased levels of ATP suggest that some energy consuming process
was operating. When respiratory chain is inhibited, e.g. by rotenone,
the F1F0-ATPase starts to function as a proton pump and hydrolyses
Fig. 6. Mitochondrial dynamics. A) Mitochondrial morphology in control (C) and patients' skin ﬁbroblasts (P1, P2, P3) not treated (pre-cccp), treated with 10 μM cccp (cccp) and
after 4 h of cccp wash out (post-cccp). Cells were ﬁxed and immunoﬂuorescence against porin was performed. B)Mitochondrial diameter in the abovementioned groups. The results
shown are the means±SD of 200 determinations. Two-way ANOVA analysis: signiﬁcant main effect for group (Pb0.001), treatment (Pb0.001) and interaction between them
(Pb0.001). *(Pb0.01) P1 vs P2. #(Pb0.001) for signiﬁcant differences between P3 and the remaining groups.
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membrane potential [for a review see 42]. Interestingly, Potlury et
al. reported increased expression levels of complex V in the other
NDUFA1 mutant described so far [38], and preliminary data from our
laboratory indicated that complex V alpha and beta subunits were also
overexpressed in P1 and P3. These results could suggest that in the
patients under the current investigation the reverse operation of
ATPase could be consuming glycolysis-derived ATP to maintain
mitochondrial membrane potential, leading to decreased ATP levels
and growth delay. This situation would be further aggravated in
DMEM-Gal, where glycolysis is running at a lower rate. Studies
investigating this possibility are underway in our laboratory.It has been described that when cells are grown in a culture
medium devoid of glucose, galactose enters slowly the glycolysis
[32,43]; this approach has been used to force the skin ﬁbroblasts
derived from mitochondrial diseased patients to get ATP through the
OXPHOS system [44–46]. In the present work a slight decrease in ATP
levels was detected in control and P2 cell lines grown in galactose, as
well as signiﬁcant decreases in P1 and P3. In control and patients' cells
grown in galactose, we also observed an increase in mitochondrial
coupling, in some respiratory chain activities, and in mitochondrial
diameter, as an adaptation to this new metabolic environment. The
reason of the slight increase in mitochondrial diameter we observed
in cells grown in DMEM-Gal is not clear, but could be related to an
Fig. 7. ROS levels in control and patients cell lines. A) Confocal images of intracellular ROS generation (green ﬂuorescence) merged with contrast-phase images from control
(C), and patient's ﬁbroblast (P1, P2, P3) cultured in high glucose DMEM (DMEM-Glu) or in galactose DMEM (DMEM-Gal). Cells were preloaded with DCF-DA to capture the
generated ROS. The confocal images represent a randomly chosen ﬁeld after 3 days of cell culture under the various experimental conditions. In each cell line a group of cells
were not loaded with DCF-DA to set the basal level of autoﬂuorescence. B) Human ﬁbroblasts from a patient suffering complex III deﬁciency non-DCF-DA loaded (left image)
and DCF-DA-loaded showing increased ROS levels (right image). C) Flow cytometry determination of ROS production in DMEM-Glu grown cells with DCF-DA probe. D)
Western blot analysis of mitochondrial superoxide dismutase (mtSOD), catalase (CAT) and glutathione reductase (GR) expression levels in control (C) and patients' (P1, P2,
P3) cells. β-actin was used as a loading control.
451M. Morán et al. / Biochimica et Biophysica Acta 1802 (2010) 443–453
452 M. Morán et al. / Biochimica et Biophysica Acta 1802 (2010) 443–453adaptation to the lower glycolytic ﬂux. Changes in mitochondrial
diameter have been reported to be associatedwith differentmetabolic
shifts [47]. For instance, the mitochondrial diameter of INS-1E cells
was augmented when glucose content was decreased in the culture
media [48]. Guillery et al. [19] reported massive mitochondrial
fragmentation in cells undergoing severe OXPHOS disorders by
glycolysis inhibition with 2-deoxyglucose. Our results do not agree
with this previous report, as P1 and P3 suffered a severe CI deﬁciency
but did not show signiﬁcant fragmentation under 2-deoxyglucose
treatment. Only an increase in mitochondrial diameter was detected
in control and P1 cell lines. This augmented mitochondrial diameter
might reﬂect a change in themetabolic state similar to that seen in the
ﬁbroblasts grown in DMEM-Gal, when glycolysis-derived ATP is
limited. Finally, the lack of massive mitochondrial fragmentation in
cell lines with marked OCR decrease under metabolic conditions that
limits the amount of glycolysis-derived ATP (i.e., DMEM-Gal or 2-
deoxyglucose treatment), supports the idea postulated by Guillery et
al. [19] that mitochondrial membrane potential is more relevant for
mitochondrial morphology than ATP levels.
Mitochondrial network morphology is the result of fusion and
ﬁssion events that allow the cell to maintain a healthy, homogeneous
mitochondrial population [21], i.e. by exchanging mitochondrial
components and eliminating non-functional mitochondria [49]. The
increased levels of OPA1 and DRP1 found in our patients' ﬁbroblasts
might reﬂect a compensatory cellular mechanism to enhance
complementation and recycling of less functional mitochondria. The
long isoforms of OPA1were predominant in both control and patients'
cells respiring in glucose and galactose conditions. This ﬁnding is in
accordance with a recent study by Guillery et al. [24] that
demonstrated a predominance of long OPA1 isoforms in CI-deﬁcient
ﬁbroblasts. Mitochondrial membrane potential is the main modulator
of OPA1 isoforms [24] and possibly of mitochondrial morphology
(more so than ATP levels) [19]. Provided that our patients' cell lines
displayed a predominance of long OPA1 isoforms and no signiﬁcant
mitochondrial fragmentation/uncoupling, we could hypothesize that
patients' cells were able to maintain mitochondrial membrane
potential in spite of their respiratory chain alteration. In support of
this hypothesis, preliminary data from our laboratory indicated that
mitochondrial membrane potential in basal culture conditions (high
glucose) was not decreased in our patients (data not shown). Slight
decreases in mitochondrial membrane potential have been described
by Distelmaier et al., in ten cell lines of their 21 patient's cohort [50].
Nevertheless, Distelmaier et al. had previously reported alterations in
mitochondrial morphology in some of these patients that could be due
to their decreased membrane potential. Also, discrepancies between
Distelmaier's data and the present work could be attributed to the
different technical approach to measure mitochondrial membrane
potential. Finally, the elevated MFN2 levels shown in P2 and P3 cells
cultured in DMEM-Gal may represent a further attempt to compen-
sate for the OXPHOS deﬁciency, i.e. by increasingmitochondrial fusion
and complementation in such metabolic stressing conditions.
To test the ﬁssion and fusion efﬁciency in our patients' cells, we
studied the kinetics of cccp-induced fragmentation and the recovery
of the mitochondrial reticulum as described by Guillery et al. [19]. The
cccp treatment led to a massive mitochondrial fragmentation that
caused a signiﬁcant increase in mitochondrial diameter in both
control and CI-deﬁcient cells. This result indicates that the ﬁssion
machinery is efﬁcient in the pathological cell lines, as previously
reported in different OXPHOS-deﬁcient ﬁbroblasts [19]. The delay
observed in mitochondrial tubule formation in P1 and P3 after
treatment suggests a mild alteration in the mitochondrial fusion
process. The decreased OCR in these two patients reﬂects a low
electron ﬂux through the respiratory chain, which could in turn result
in a delayed recovery of the mitochondrial membrane potential after
the cccp treatment. Because mitochondrial membrane potential is
required for efﬁcient fusion [51] a delayed restoration of thisparameter could induce a subsequent delay in the recovery of
mitochondrial morphology after cccp treatment; yet, this hypothesis
remains to be elucidated.
ROS production can increase in ﬁbroblasts from CI-deﬁcient
patients, with larger increases being found in the more severe CI
deﬁciencies [13–15]. In the present work none of the patients' cells
lines showed increased ROS levels. One of the factors that determines
the rate of O2·− production by mitochondria is the concentration of
enzymes/proteins containing electron carriers that can react with O2
to form O2·− [52]. Together with complex III, CI is one of the
mitochondrial sites responsible for ROS production. Given that our
NDUFA1 mutants presented decreased levels of fully-assembled CI
[25], a hypothetic increased ROS production due to abnormal function
of respiratory chain, could be counteracted by the lowered CI levels.
This would explain the normal ROS levels found in these two patients.
Nevertheless, signiﬁcant amounts of ROS have been described in
ﬁbroblasts with decreased CI levels [50]. Another possibility is that an
increased antioxidant defence in the patient's cells could have
counteracted the increased ROS production. Yet, in the present work
only P2 cells showed augmented expression levels of mtSOD, with the
other key antioxidant enzymes remaining unchanged. Although in
this patient the increase in mtSOD could suggest an increase in ROS
production, increases in antioxidant defences cannot explain, as a
general rule, the absence of increases in ROS levels in the present
study. Moreover, Verkaart et al. [14,15] studied ROS production in two
patients harbouring mutations in the NDUFV1 gene, ﬁnding increased
ROS levels in one case and no alterations in the other mutant. The
effect of NDUFV1 mutations, and in other CI subunits, on ROS
production would depend on several factors such as: their effects on
NADH binding and NADH oxidation by FMN, the electron ﬂux through
the complex, or the interactions between the mutated and other CI
subunits. Therefore, opposite effects in ROS production of different
mutations are possible. Further mechanistic studies are needed to
unravel their impact on ROS production.
In conclusion, severe CI deﬁciency in patients harbouring muta-
tions in the NDUFA1 and NDUFV1 genes is linked to a delayed
mitochondrial network recovery after cccp treatment, but not to
massive mitochondrial fragmentation or to increased ROS levels.
These results suggest that the different genetic backgrounds of
patients with OXPHOS disorders might play a role in the pathophys-
iologic manifestations of the mutations.Acknowledgements
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